Your browser doesn't support javascript.
loading
The Cooperation of IL-29 and PLGA Nanoparticles Improves the Protective Immunity of the gD-1 DNA Vaccine Against Herpes Simplex Virus Type 1 in Mice.
Amir Kalvanagh, Parisa; Karimi, Hesam; Soleimanjahi, Hoorieh; Ebtekar, Massoumeh; Kokhaei, Parviz; Matloubi, Zahra; Rahimi, Roghieh; Kazemi-Sefat, Nazanin Atieh; Rajaei, Hajar.
Afiliación
  • Amir Kalvanagh P; Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
  • Karimi H; Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
  • Soleimanjahi H; Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
  • Ebtekar M; Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
  • Kokhaei P; Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran.
  • Matloubi Z; Department of Immunology, Faculty of Medical Sciences, Sabzevar University, Sabzevar, Iran.
  • Rahimi R; Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
  • Kazemi-Sefat NA; Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
  • Rajaei H; Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Immunol Invest ; 52(7): 779-795, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37610337
In clinical practice, the low immunogenicity and low stability of the DNA plasmid vaccine candidates are two significant shortcomings in their application against infectious diseases. To overcome these two disadvantages, the plasmid expressing IL-29 (pIL-29) as a genetic adjuvant and polylactic-co-glycolic acid (PLGA) as a non-viral delivery system were used, respectively. In this study, the pIL-29 encapsulated in PLGA nanoparticles (nanoIL-29) and the pgD1 encapsulated in PLGA nanoparticles (nanoVac) were simultaneously applied to boost immunologic responses against HSV-1. We generated spherical nanoparticles with encapsulation efficiency of 75 ± 5% and sustained the release of plasmids from them. Then, Balb/c mice were subcutaneously immunized twice with nanoVac+nanoIL-29, Vac+IL-29, nanoVac, Vac, nanoIL-29, and/or IL-29 in addition to negative and positive control groups. Cellular immunity was evaluated via lymphocyte proliferation assay, cytotoxicity test, and IFN-γ, IL-4, and IL-2 measurements. Mice were also challenged with 50X LD50 of HSV-1. The nanoVac+nanoIL-29 candidate vaccine efficiently enhances CTL and Th1-immune responses and increases the survival rates by 100% in mice vaccinated by co-administration of nanoVac and nanoIL-29 against the HSV-1 challenge. The newly proposed vaccine is worth studying in further clinical trials, because it could effectively improve cellular immune responses and protected mice against HSV-1.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Herpesvirus Humano 1 / Vacunas de ADN / Nanopartículas Límite: Animals Idioma: En Revista: Immunol Invest Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Herpesvirus Humano 1 / Vacunas de ADN / Nanopartículas Límite: Animals Idioma: En Revista: Immunol Invest Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido